Participant flow

A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer · Source last updated 2024-04-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Participants received 150 milligrams (mg) LY3475070 orally once daily (QD) on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.

   id

   FG000

   title

   Cohort A - 150mg QD LY3475070

2. description

   Participants received 300mg LY3475070 orally once daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.

   id

   FG001

   title

   Cohort A - 300mg QD LY3475070

3. description

   Participants received 300mg LY3475070 orally twice daily (BID) on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.

   id

   FG002

   title

   Cohort A - 300mg BID LY3475070

4. description

   Participants received 600mg LY3475070 orally once daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.

   id

   FG003

   title

   Cohort A - 600mg QD LY3475070

5. description

   Participants received 150mg LY3475070 orally once daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.

   id

   FG004

   title

   Cohort B - 150mg QD LY3475070 + Pembrolizumab

6. description

   Participants received 150mg LY3475070 orally twice daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.

   id

   FG005

   title

   Cohort B - 150mg BID LY3475070 + Pembrolizumab

7. description

   Participants received 300mg LY3475070 orally once daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.

   id

   FG006

   title

   Cohort B - 300mg QD LY3475070 + Pembrolizumab

8. description

   Participants received 300mg LY3475070 orally twice daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study

   id

   FG007

   title

   Cohort B - 300mg BID LY3475070 + Pembrolizumab

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      3. group Id

         FG002

         num Subjects

         0

      4. group Id

         FG003

         num Subjects

         1

      5. group Id

         FG004

         num Subjects

         0

      6. group Id

         FG005

         num Subjects

         1

      7. group Id

         FG006

         num Subjects

         1

      8. group Id

         FG007

         num Subjects

         0

      type

      Withdrawal by Subject

   2. reasons

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      3. group Id

         FG002

         num Subjects

         1

      4. group Id

         FG003

         num Subjects

         0

      5. group Id

         FG004

         num Subjects

         0

      6. group Id

         FG005

         num Subjects

         2

      7. group Id

         FG006

         num Subjects

         0

      8. group Id

         FG007

         num Subjects

         0

      type

      Lost to Follow-up

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         4

      2. group Id

         FG001

         num Subjects

         6

      3. group Id

         FG002

         num Subjects

         6

      4. group Id

         FG003

         num Subjects

         4

      5. group Id

         FG004

         num Subjects

         3

      6. group Id

         FG005

         num Subjects

         11

      7. group Id

         FG006

         num Subjects

         1

      8. group Id

         FG007

         num Subjects

         17

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         4

      2. group Id

         FG001

         num Subjects

         6

      3. group Id

         FG002

         num Subjects

         6

      4. group Id

         FG003

         num Subjects

         4

      5. group Id

         FG004

         num Subjects

         3

      6. group Id

         FG005

         num Subjects

         11

      7. group Id

         FG006

         num Subjects

         1

      8. group Id

         FG007

         num Subjects

         17

      type

      Received at Least 1 Dose of Study Drug

   3. achievements

      1. group Id

         FG000

         num Subjects

         4

      2. group Id

         FG001

         num Subjects

         6

      3. group Id

         FG002

         num Subjects

         5

      4. group Id

         FG003

         num Subjects

         3

      5. group Id

         FG004

         num Subjects

         3

      6. group Id

         FG005

         num Subjects

         8

      7. group Id

         FG006

         num Subjects

         0

      8. group Id

         FG007

         num Subjects

         17

      comment

      Completers include participants who were observed until event (progressive disease or death) or had discontinued study treatment and was in follow up at the time of the final analysis.

      type

      COMPLETED

   4. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      3. group Id

         FG002

         num Subjects

         1

      4. group Id

         FG003

         num Subjects

         1

      5. group Id

         FG004

         num Subjects

         0

      6. group Id

         FG005

         num Subjects

         3

      7. group Id

         FG006

         num Subjects

         1

      8. group Id

         FG007

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

recruitment Details

The study was initially designed to be conducted in two phases: Phase 1a (dose escalation cohorts A, B) and Phase 1b (dose expansion cohorts C1, C2, D1, D2, E). Based on Sponsor decision, Phase 1b expansion cohorts were not initiated, no participants were enrolled.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice